More than 65 industry players across the world are presently engaged in evaluating the clinical{Root

Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this – https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:
 Target Disease Indication
 Cancer
 Genetic Disorders
 Neurological Indications
 Others

 Route of Administration
 Oral
 Inhalation

 Key Geographies
 North America
 Europe
Asia-Pacific and the Rest of the World

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:
 GW Pharmaceuticals
 Corbus Pharmaceuticals
 Tilray
 Tetra Bio-Pharma
 Botanix Pharmaceuticals
 Kalytera Therapeutics
 Therapix Biosciences
 Echo Pharmaceuticals
 Avicanna
 GB Sciences

Table of Contents

1. PREFACE

2. EXECUTIVE SUMMARY

3. INTRODUCTION

4. MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

5. COMPANY PROFILES

6. ACADEMIC GRANTS ANALYSIS

7. PARTNERSHIPS AND COLLABORATIONS

8. MERGERS AND ACQUISITIONS

9. DRUG DEVELOPMENT STRATEGY ANALYSIS
10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

Leave a Reply

Your email address will not be published. Required fields are marked *